^
Association details:
| Biomarker: | KRAS exon 13 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 4325: A Phase II exploratory study to identify biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer who have failed first-line therapy
Published date:
05/15/2020
Excerpt:
However, KRAS mutations in exons 12 and 13 appeared enriched in intrinsically resistant lesions compared to stable and acquired resistance lesions (83% versus 41%).
DOI:
10.1158/1538-7445.AM2020-4325
